β-Amyloid Antibody (6C3): sc-517461
- β-Amyloid Antibody (6C3) is a mouse monoclonal IgG2b, cited in 1 publications, provided at 200 µg/ml
- raised against recombinant oligomeric β-Amyloid of human origin
- recommended for detection of β-Amyloid of human origin by WB
- m-IgG2b BP-HRP is the preferred secondary detection reagent for β-Amyloid Antibody (6C3) for WB applications. This reagent is now offered in a bundle with β-Amyloid Antibody (6C3) (see ordering information below).
QUICK LINKS
β-Amyloid Antibody (6C3) is a mouse monoclonal IgG2b antibody that detects β-Amyloid in human samples through western blotting (WB). β-Amyloid is a critical peptide derived from the proteolytic cleavage of the Amyloid precursor protein (APP), and accumulation of β-Amyloid is a hallmark of Alzheimer′s disease, as well as being implicated in other neurological disorders and type II diabetes. β-Amyloid formation is particularly significant because β-Amyloid contributes to the development of neurofibrillary tangles and senile plaques, which are pathological features observed in the brains of Alzheimer′s patients. Understanding β-Amyloid structure is essential, as β-Amyloid exists in various forms, including soluble and insoluble aggregates, which can influence neurotoxic properties and interactions with other proteins. Notably, β-Amyloid interacts with several key proteins, including apolipoprotein E (ApoE), which plays a role in lipid metabolism and is also associated with Alzheimer′s disease risk. Anti-β-Amyloid antibody (6C3) specifically targets β-Amyloid, making this antibody an invaluable tool for researchers studying the mechanisms of amyloid pathology and the development of therapeutic strategies aimed at mitigating β-Amyloid accumulation in neurodegenerative diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
β-Amyloid Antibody (6C3) References:
- Towards Alzheimer's beta-amyloid vaccination. | Frenkel, D. and Solomon, B. 2001. Biologicals. 29: 243-7. PMID: 11851323
- Beta-amyloid accumulation in neurovascular units following brain embolism. | Han, F. and Fukunaga, K. 2009. J Pharmacol Sci. 111: 101-9. PMID: 19783863
- Membrane channel hypothesis of lysosomal permeabilization by beta-amyloid. | Zaretsky, DV., et al. 2022. Neurosci Lett. 770: 136338. PMID: 34767924
- Beta-Amyloid Instigates Dysfunction of Mitochondria in Cardiac Cells. | Jang, S., et al. 2022. Cells. 11: PMID: 35159183
- Bleomycin modulates amyloid aggregation in β-amyloid and hIAPP. | Kumari, A., et al. 2020. RSC Adv. 10: 25929-25946. PMID: 35518630
- Modulation of beta-amyloid aggregation using ascorbic acid. | Sampaio, I., et al. 2022. Biochimie. 200: 36-43. PMID: 35588896
- Spatial association between distributed β-amyloid and tau varies with cognition. | Carbonell, F., et al. 2023. bioRxiv.. PMID: 37808643
- Lower levels of soluble β-amyloid precursor protein, but not β-amyloid, in the frontal cortex in schizophrenia. | Dean, B., et al. 2024. Psychiatry Res. 331: 115656. PMID: 38071879
- Neurotoxicity of beta-amyloid and prion peptides. | Forloni, G. 1996. Curr Opin Neurol. 9: 492-500. PMID: 9007411
- Oxidative mechanisms in beta-amyloid cytotoxicity. | Davis, JB. 1996. Neurodegeneration. 5: 441-4. PMID: 9117560
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
β-Amyloid Antibody (6C3) | sc-517461 | 200 µg/ml | $322.00 | |||
β-Amyloid Antibody (6C3): m-IgG2b BP-HRP Bundle | sc-548637 | 200 µg Ab; 10 µg BP | $361.00 |